We are live on ! Find out more
ASBPW

Aspire Biopharma Warrant
ASBPW

27 hedge funds and large institutions have $667K invested in Aspire Biopharma Warrant in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

7% more capital invested

Capital invested by funds: $624K → $667K (+$42.5K)

4% more funds holding

Funds holding: 26 → 27 (+1)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

Holders
27
Holders Change
+1
Holders Change %
+3.85%
% of All Funds
0.36%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
2
Reduced
2
Closed
4
Calls
$19K
Puts
–
Net Calls
+$19K
Net Calls Change
+$6K

Top Buyers

Rank Fund Capital Flow
1
SC
Sculptor Capital
New York
+$115K
2
AC
Aristeia Capital
Connecticut
+$41K
3
AIMCA
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
+$15.1K
4
CS
Clear Street
New York
+$11.6K
5
FTUS
Flow Traders U.S.
New York
+$854

Top Sellers

Rank Fund Capital Flow
1
AA
AQR Arbitrage
Connecticut
-$30.8K
2
WAM
Wolverine Asset Management
Illinois
-$12.4K
3
PC
Periscope Capital
Ontario, Canada
-$8.77K
4
Nomura Holdings
Nomura Holdings
Japan
-$7.2K
5
Walleye Trading
Walleye Trading
New York
-$621
Name Holding Trade Value Shares
Change 		Change in
Stake
HCM
1
Highbridge Capital Management
New York
$101K – – –
SCM
2
Saba Capital Management
New York
$71.8K – – –
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$71.1K – – –
LA
4
Linden Advisors
New York
$65.7K – – –
AC
5
Aristeia Capital
Connecticut
$49.8K +$41K +681,516 New
SC
6
Sculptor Capital
New York
$36.5K +$115K +1,905,000 +381%
Barclays
7
Barclays
United Kingdom
$31.4K – – –
PC
8
Periscope Capital
Ontario, Canada
$29.8K -$8.77K -145,633 -26%
Verition Fund Management
9
Verition Fund Management
Connecticut
$29.3K – – –
CS
10
Clear Street
New York
$22.4K +$11.6K +192,598 +139%
TCA
11
Taconic Capital Advisors
New York
$20.3K – – –
AIMCA
12
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$16.9K +$15.1K +250,000 New
MTCM
13
Mint Tower Capital Management
Netherlands
$15K – – –
D.E. Shaw & Co
14
D.E. Shaw & Co
New York
$13.5K – – –
WAM
15
Wolverine Asset Management
Illinois
$13.3K -$12.4K -205,600 -51%
AC
16
Athos Capital
Hong Kong
$12K – – –
CCM
17
Context Capital Management
California
$11.8K – – –
PAMP
18
Polar Asset Management Partners
Ontario, Canada
$10.1K – – –
LP
19
LMR Partners
United Kingdom
$8.46K – – –
WA
20
Whitebox Advisors
Minnesota
$8.04K – – –
CSD
21
Clear Street Derivatives
New York
$7.18K – – –
JP Morgan Chase
22
JP Morgan Chase
New York
$6.77K – – –
CCM
23
CAAS Capital Management
New York
$5.08K – – –
BOCH
24
Blue Owl Capital Holdings
New York
$3.5K – – –
PMAM
25
Picton Mahoney Asset Management
Ontario, Canada
$3K – – –
1
2

ASBPW Hedge Fund Activity: Q1 2025 in Review

27 of the 7,462 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q1 2025, worth a combined $667K — up 6.8% from $624K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new ASBPW positions and 4 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Sculptor Capital, adding an estimated $115K. The largest seller was AQR Arbitrage, exiting entirely with an estimated $30.8K sold.

  • 27 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q1 2025, up from 26 in Q4 2024.
  • Funds reported $667K of Aspire Biopharma Warrant stock for Q1 2025, up 6.8% quarter-over-quarter.
  • 5 funds opened new Aspire Biopharma Warrant positions in Q1 2025 and 4 closed out, a net change of +1 holder.
  • The largest Aspire Biopharma Warrant buyer in Q1 2025 was Sculptor Capital, an estimated $115K added.
  • The largest Aspire Biopharma Warrant seller in Q1 2025 was AQR Arbitrage, an estimated $30.8K sold.

Based on aggregated 13F filings for Q1 2025.